MX2024003076A - Compuestos espirociclicos. - Google Patents
Compuestos espirociclicos.Info
- Publication number
- MX2024003076A MX2024003076A MX2024003076A MX2024003076A MX2024003076A MX 2024003076 A MX2024003076 A MX 2024003076A MX 2024003076 A MX2024003076 A MX 2024003076A MX 2024003076 A MX2024003076 A MX 2024003076A MX 2024003076 A MX2024003076 A MX 2024003076A
- Authority
- MX
- Mexico
- Prior art keywords
- spirocyclic compounds
- compounds
- relates
- processes
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La memoria descriptiva se refiere a compuestos de Fórmula (I) (ver Fórmula) (I) y sales farmacéuticamente aceptables de estos. La memoria descriptiva también se refiere a procesos y productos intermedios usados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243267P | 2021-09-13 | 2021-09-13 | |
| PCT/EP2022/075248 WO2023036974A1 (en) | 2021-09-13 | 2022-09-12 | Spirocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003076A true MX2024003076A (es) | 2024-03-27 |
Family
ID=83688613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003076A MX2024003076A (es) | 2021-09-13 | 2022-09-12 | Compuestos espirociclicos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11939344B2 (es) |
| EP (1) | EP4402143A1 (es) |
| JP (1) | JP7406674B2 (es) |
| KR (1) | KR102624567B1 (es) |
| CN (1) | CN117916241A (es) |
| AR (1) | AR127050A1 (es) |
| AU (1) | AU2022343903A1 (es) |
| CA (1) | CA3230648A1 (es) |
| CO (1) | CO2024002844A2 (es) |
| CR (1) | CR20240160A (es) |
| DO (1) | DOP2024000041A (es) |
| EC (1) | ECSP24028270A (es) |
| IL (1) | IL311254A (es) |
| MX (1) | MX2024003076A (es) |
| PE (1) | PE20240886A1 (es) |
| TW (1) | TW202330538A (es) |
| WO (1) | WO2023036974A1 (es) |
| ZA (1) | ZA202400595B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024038004A1 (en) | 2022-08-15 | 2024-02-22 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| WO2024188999A1 (en) | 2023-03-13 | 2024-09-19 | Astrazeneca Ab | Crystalline form |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324483B1 (en) * | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
| US8455477B2 (en) * | 2008-08-05 | 2013-06-04 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| CN109415336B (zh) | 2016-04-06 | 2023-08-29 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| SG11202103282YA (en) | 2018-10-08 | 2021-04-29 | Univ Michigan Regents | Small molecule mdm2 protein degraders |
-
2022
- 2022-09-12 MX MX2024003076A patent/MX2024003076A/es unknown
- 2022-09-12 KR KR1020237019818A patent/KR102624567B1/ko active IP Right Grant
- 2022-09-12 JP JP2023534129A patent/JP7406674B2/ja active Active
- 2022-09-12 AU AU2022343903A patent/AU2022343903A1/en active Pending
- 2022-09-12 CN CN202280059862.4A patent/CN117916241A/zh active Pending
- 2022-09-12 TW TW111134225A patent/TW202330538A/zh unknown
- 2022-09-12 PE PE2024000416A patent/PE20240886A1/es unknown
- 2022-09-12 EP EP22786303.2A patent/EP4402143A1/en active Pending
- 2022-09-12 WO PCT/EP2022/075248 patent/WO2023036974A1/en active Application Filing
- 2022-09-12 CA CA3230648A patent/CA3230648A1/en active Pending
- 2022-09-12 CR CR20240160A patent/CR20240160A/es unknown
- 2022-09-12 IL IL311254A patent/IL311254A/en unknown
- 2022-09-13 AR ARP220102479A patent/AR127050A1/es unknown
-
2023
- 2023-06-15 US US18/335,225 patent/US11939344B2/en active Active
-
2024
- 2024-01-17 ZA ZA2024/00595A patent/ZA202400595B/en unknown
- 2024-02-16 US US18/443,829 patent/US20240270757A1/en active Pending
- 2024-03-06 DO DO2024000041A patent/DOP2024000041A/es unknown
- 2024-03-07 CO CONC2024/0002844A patent/CO2024002844A2/es unknown
- 2024-04-11 EC ECSENADI202428270A patent/ECSP24028270A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102624567B1 (ko) | 2024-01-11 |
| WO2023036974A1 (en) | 2023-03-16 |
| AR127050A1 (es) | 2023-12-13 |
| TW202330538A (zh) | 2023-08-01 |
| ZA202400595B (en) | 2024-09-25 |
| CN117916241A (zh) | 2024-04-19 |
| EP4402143A1 (en) | 2024-07-24 |
| US20230357279A1 (en) | 2023-11-09 |
| DOP2024000041A (es) | 2024-04-15 |
| KR20230091198A (ko) | 2023-06-22 |
| US11939344B2 (en) | 2024-03-26 |
| CO2024002844A2 (es) | 2024-03-18 |
| ECSP24028270A (es) | 2024-05-31 |
| PE20240886A1 (es) | 2024-04-24 |
| IL311254A (en) | 2024-05-01 |
| AU2022343903A1 (en) | 2024-05-02 |
| JP7406674B2 (ja) | 2023-12-27 |
| JP2023549418A (ja) | 2023-11-24 |
| CR20240160A (es) | 2024-05-30 |
| US20240270757A1 (en) | 2024-08-15 |
| CA3230648A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| CR20210504A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| PH12021550166A1 (en) | Nlrp3 inflammasome inhibitors | |
| ZA202400595B (en) | Spirocyclic compounds | |
| SA521430853B1 (ar) | Nlrp3 مثبطات جسيم التهابي | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| PH12019501724A1 (en) | Estrogen receptor modulators | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| MX2024000999A (es) | Antagonista de molécula pequeña de lpa1. | |
| MX2023009285A (es) | Compuestos novedosos. | |
| PH12021550557A1 (en) | Furo[3,4-b]pyrrole-containing btk inhibitor | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| WO2022204344A3 (en) | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents | |
| EA202092600A1 (ru) | Тетрациклические гетероарильные соединения | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| EA201990943A1 (ru) | 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА |